TLR3 and COVID-19: Rintatolimod, a Toll-like receptor 3 (TLR3) agonist, was reported to exert antiviral effects in human pancreatic cancer cells by activating the innate immune system, suggesting it could be used in the treatment of cancer patients who suffer from SARS-CoV-2 infection.329 Poly-ICLC is a synthetic complex of carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine dsRNA.330 A phase I trial to study the safety and immunogenicity of poly-ICIC in healthy vaccinated COVID-19 adults is in its recruitment stage.